NCT03520751View on ClinicalTrials.gov

Phase I/IIa Trial of scAAV1.tMCK.NTF3 for Treatment of CMT1A

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

3

Participants

Timeline

Start Date

April 30, 2027

Primary Completion Date

April 30, 2029

Study Completion Date

April 30, 2030

Conditions

Charcot-Marie-Tooth Neuropathy Type 1A

Interventions

DRUG

scAAV1.tMCK.NTF3

gene vector

Trial Locations (1)

43205

Nationwide Children's Hospital, Columbus

All Listed Sponsors

lead

Nationwide Children's Hospital

OTHER